Morphine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Morphine: From Severe Pain to Myofascial Pain Syndrome
One-Sentence Summary
Morphine is an opioid analgesic that is marketed in South Africa, though the SAHPRA registration records do not state an approved indication. The TxGNN model predicts it may be effective for Myofascial Pain Syndrome, but 33 registered trials and 17 publications contain no trial testing morphine in this condition. The prediction is therefore a hypothesis only, not an evidence-backed direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain relief (opioid analgesic). The SAHPRA records provided do not state an indication text. |
| Predicted New Indication | Myofascial pain syndrome |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general pharmacology, morphine is a mu-opioid receptor agonist that produces central and peripheral analgesia. In principle this could relieve musculoskeletal pain such as myofascial pain.
The link between the original and new indication is therefore “pain to pain”, and it is weak. The 33 matched trials are mostly non-drug or non-morphine studies (dry needling, exercise, photobiomodulation, brain stimulation) that were matched on the word “pain”. The only direct signal is a 2026 study of morphine as an adjuvant in myofascial infiltration during spinal fusion surgery. Its design cannot be verified from the available record.
Opioids are generally not favoured for chronic myofascial pain because of dependence and hyperalgesia risk. Any future work should be limited to perioperative or infiltration adjunct use.
Clinical Trial Evidence
None of the trials below tests morphine for myofascial pain syndrome. They are the closest matches among the 33 registered trials.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00580294 | N/A | Completed | 12 | Pilot of rapid rotation from morphine or oxycodone to oxymorphone in chronic pain. Opioid-class evidence only, with no controlled efficacy endpoint. |
| NCT06955923 | Phase 2 | Completed | 11 | Trigger point injections versus sham after knee replacement, aiming to reduce pain and opioid use. Non-opioid, no morphine arm. |
| NCT04640896 | Phase 4 | Recruiting | 60 | Trigger point injections versus traditional therapies for pain after anterior cervical surgery. |
| NCT04504812 | Phase 3 | Completed | 1937 | Sequenced non-surgical strategy for knee osteoarthritis pain, aimed at reducing opioid reliance. Not a morphine study. |
| NCT07413770 | N/A | Recruiting | 60 | Classical massage in myofascial pain syndrome. Non-drug. |
| NCT05478928 | N/A | Unknown | 60 | Invasive physiotherapy techniques (microelectrolysis, dry needling) in myofascial trigger points. Non-drug. |
| NCT04684784 | N/A | Completed | 46 | Dry needling versus sham on electromyographic activity in latent trigger points. Non-drug. |
| NCT05050656 | Phase 4 | Completed | 70 | Preoperative duloxetine and its effect on spinal anaesthesia and early postoperative pain. |
| NCT03271151 | Phase 4 | Completed | 160 | Duloxetine and opioid use after knee replacement. Tests an opioid-sparing strategy. |
| NCT01878019 | N/A | Completed | 92 | Brain responses to pain in chronic pain patients, using naloxone (an opioid antagonist). Mechanistic study. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41664327 | 2026 | Randomised trial (double-blind) | Asian Spine J | Dexmedetomidine plus morphine versus plain ropivacaine for myofascial infiltration in thoracolumbar spinal fusion. This is the only direct morphine and myofascial signal, and the design cannot be verified from the title. |
| 17870625 | 2008 | RCT | Eur J Pain | Epidural bupivacaine and morphine compared with intercostal nerve cryoanalgesia for post-thoracotomy pain in 107 patients. Not myofascial pain. |
| 35066974 | 2022 | Cohort | Pain Pract | Structured stretching programme for myofascial pain and opioid usage in “legacy pain” patients. |
| 22648287 | 2012 | Clinical study | J Anesth | Cervical facet joint injections added to multimodal treatment of long-standing cervical myofascial pain. |
| 21419546 | 2011 | Retrospective/observational | J Oral Maxillofac Surg | Long-term opioid use in temporomandibular joint dysfunction. The evidence can be neither supported nor refuted. |
| 16713811 | 2006 | Clinical report | J Oral Maxillofac Surg | Arthrocentesis followed by intra-articular morphine infusion for refractory temporomandibular joint pain. |
| 20390305 | 2010 | Clinical study | Schmerz | Altered pain thresholds during and after opioid withdrawal in chronic low back pain. |
| 39793344 | 2025 | Clinical study | Eur J Obstet Gynecol Reprod Biol | Pudendal nerve block for pain after OnabotulinumtoxinA injection for myofascial pelvic pain. |
| 5654625 | 1968 | Narrative review | Br Med J | “Pain in the face”. Historical overview with no morphine-specific evidence. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. BV329 | Opium Camphorated Tinct | Liquid |
| Reg. No. B769 (ACT 101) | Cyclimorph 1ml | Injection |
| Reg. No. G2815 | Toothache Essence (Dozen) | Liquid |
The registry records provided do not include approved indication text or manufacturer names. Essential Medicines List (EML) status could not be determined from the data supplied.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
The evidence review also raised class-level concerns that matter for this prediction: dependence, opioid-induced hyperalgesia, and the general unsuitability of opioids for chronic myofascial pain. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The model score is very high (99.75%), but no trial tests morphine in myofascial pain syndrome and no Phase 3 RCT supports it. The retrieved trials are almost all non-morphine or non-drug studies matched on the word “pain”, and the risk-benefit balance for chronic use is unfavourable.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications, which are needed before any safety screening
- Mechanism of action data
- The full text and design of the 2026 morphine myofascial infiltration study (PMID 41664327), to confirm whether it is a real morphine signal
- A defined, limited use case (perioperative or infiltration adjunct) with a dependence and hyperalgesia monitoring plan
- Consideration of the other predicted indications first. Restless legs syndrome has stronger, morphine-specific observational evidence (L3), including intrathecal morphine reports and a national opioid registry.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.